Ｐａｇｅ 121490 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 通常モードに戻る ┃ ＩＮＤＥＸ ┃ ≪前へ │ 次へ≫ ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ ▼EMEA Recommendz a N fuesitiouri 08/7/4(金) 14:59 ─────────────────────────────────────── ■題名 ： EMEA Recommendz a N ■名前 ： fuesitiouri <jateexesced@antimir.net> ■日付 ： 08/7/4(金) 14:59 ■Ｗｅｂ ： http://google.com/rczaoa -------------------------------------------------------------------------
| LONDON, June 19, 2008-The European Medicines instrumentality (EMEA) has recommended updating thge yield report for epoetin-contgaining meidcines with a new caution for their use in cancer patients stating that blood transfusion should be the preferred method of correcting anaemia in patients hardship cancer. Epoetin-containing medicines are indicated in patients with great-lasting achat levitra generique incompetent and for the treatment of anaemia in symptomatic patients with non-myeloid growths receiving chemotherapy. The power痴 council for remedial Prdoucts for sympathetic Use (CHMP) had periodicaled new facts from studesi that showed an inrceased hazard of growth acheter levitra development, venous thromboembolism and shorter inclusive survival in cancer patients who cleard epoetins compared to patients who did not epxerience them. Following this rehashing, the CHMP concluded, atits June 2008 union, that the gains of epoetins persistachat cialis surapss their hazards in the approved indications. on the other hand, in cancer patienys with a reasonably lengthy existence-expectancy, the emoluments of using epoetins does not surpass the endanger achat cialis growth movement forward and shorter all-incluszive survival and consequently the cabinet concluded that in these patients anaemia should be corrected with blood transfusioins. |